F 18 T807 Tau PET Imaging of Progressive Posterior Cortical Dysfunction (IND 123119, Protocol E)

Study Overview
=================
Brief Summary
-----------------
This project will collect quantitative pilot data that will allow the characterization of uptake and binding of 18F-AV-1451 (also known as F 18 T807), a novel tau imaging compound, in individuals with Progressive Posterior Cortical Dysfunction (PPCD) and logopenic variant primary progressive aphasia (lvPPA). The primary goal is to develop tau imaging technique as an antecedent biomarker of cognitive decline. The investigators propose to obtain preliminary data that will support the possibility of detecting cognitive decline in its earliest stages, before the occurrence of dementia.

Official Title
-----------------
F 18 T807 Tau PET Imaging of Progressive Posterior Cortical Dysfunction Due to Alzheimer Disease

Conditions
-----------------
Alzheimer Disease, Progressive Posterior Cortical Dysfunction (PPCD)

Intervention / Treatment
-----------------
* Drug: F 18 T807


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female participants, at least 45 years of age. Clinical diagnosis of PPCD. Participant is able and willing to undergo testing (MRI or CT, PET, radioactive tracer injection, LP; for those unable to undergo an MRI, CT will be used to generate regions-of-interest). Pre-menopausal women will have a negative urine pregnancy test within 24 hours of T807 drug administration. Exclusion Criteria: Has any condition that, in the Investigator's opinion, could increase risk to the participant, limit the participant's ability to tolerate the experimental procedures, or interfere with the collection/analysis of the data (for example, participants with severe chronic back pain might not be able to lie still during the scanning procedures). Is deemed likely unable to perform the imaging procedures for any reason. Has a high risk for Torsades de Pointes or is taking medications known to prolong QT interval. Has hypersensitivity to F 18 T807 or any of its excipients. Contraindications to PET, PET-CT or MR (e.g. electronic medical devices, inability to lie still for long periods) that make it unsafe for the individual to participate. Severe claustrophobia. Currently pregnant or breast-feeding. For those electing to undergo the optional lumbar puncture: on anticoagulant of any form prior to lumbar puncture.

Ages Eligible for Study
-----------------
Minimum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental F 18 T807<br> | Drug: F 18 T807<br>* Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.<br>* Other names: 18F-AV-1451;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| F 18 T807 Standard Uptake Value Ratios (SUVR) will be correlated with other imaging modalities (MRI, PET amyloid imaging) and cognitive performance. |  | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Dementia, Brain Diseases, mild cognitive impairment, Central Nervous System Diseases, Neurodegenerative Disease